New combo therapy aims to shrink advanced throat cancer

NCT ID NCT06059261

Recruiting now Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Feb 19, 2026 · Last updated May 21, 2026 · Updated 15 times

Summary

This study tests whether adding the drug envafolimab to standard chemoradiation and another drug (endostatin) can better shrink tumors in people with advanced nasopharyngeal cancer. About 30 adults aged 18-65 with stage III-IVA disease will receive the combination. The main goal is to see how many patients have a complete disappearance of their cancer after initial treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NASOPHARYNGEAL CARCINOMA